Objective: Vitamin D deficiency has been associated with cardiovascular disease. The aim of this study was to determine serum concentration of 25 hydroxyvitamin D (25(OH)D) in patients with acute coronary syndrome (ACS) and to assess the prognostic role of serum vitamin D level in ACS patients during 3-year follow up.
INTRODUCTION
Vitamin D is a precursor of the steroid hormone calcitriol which is necessary for mineral homeostasis and bone metabolism (1) . Upon vitamin D discovery in almost all body cells, such as immune system, vascular and myocardial cells, a more diversified role of vitamin D than previously believed has been recognized. This has resulted in extensive research into the role of vitamin D in the pathogenesis of chronic non-skeletal diseases such as infectious, autoimmune, malignant, and cardiovascular diseases (CVD) (2) .
Cardiovascular risk factors such as arterial hypertension, obesity, dyslipidemia, and diabetes mellitus (DM), and the resulting CVD including acute coronary syndrome (ACS), coronary artery disease (CAD) and stroke are the most prevalent illnesses and the leading causes of death worldwide. Therefore, it is of utmost importance to determine the role of vitamin D in CVD.
Vitamin D deficiency has been recorded all over the world. Estimates of vitamin D status in various European countries show great differences. According to literature data, the prevalence of vitamin D deficiency is between 2% and 30% in adult European population; however, some studies report a figure as high as 75% in elderly institutionalized individuals. Accordingly, vitamin D deficiency has grown into a major public health problem (3 (4, 5) . There is ever more evidence pointing to a U-shaped curve for several vitamin D level associated health outcomes, including CVD and all-cause mortality, the risk being lowest at moderate but increased at low and high 25(OH) D levels (6) .
Vitamin D deficiency was found in patients with ACS and preliminary studies suggest it to be potentially associated with prognosis as well. However, convincing evidence confirming the impact of vitamin D insufficiency or deficiency on ACS patient morbidity and mortality is still lacking (7) . The biological mechanism of vitamin D deficiency in ACS is not simple; we can only speculate on a dual effect of vitamin D in ACS, i.e. its direct immunomodulatory action and indirect action on the known cardiovascular risk factors.
There is evidence for vitamin D to suppress the renin-angiotensin system and to influence endothelial function, inflammatory processes, platelet function, insulin resistance, and blood pressure (8) . All these effects are highly relevant in ACS influencing the patient clinical course. In addition, low vitamin D level has been associated with ventricular dysfunction and cardiac remodeling following ACS, as well as with heart failure and sudden cardiac death (9) (10) (11) (12) . Therefore, it appears that vitamin D level can influence both short-term and long-term outcomes in ACS patients.
The aim of the present study was to analyze serum 25(OH)D levels in ACS patients in comparison to ACS-free control group, to assess the association of CAD and serum 25(OH)D levels in ACS patients, and to evaluate the ACS patient prognosis according to serum 25(OH)D levels for the first time in a homogeneous Caucasian population in Croatia.
MATERIALS AND METHODS

Study Population
The study included 60 patients treated for ACS at Dr Josip Benčević General Hospital in Slavonski Brod, Croatia, from March 2012 till October 2012, and 60 subjects not treated for any form of ischaemic heart disease before enrolment in the study as a control group. We included patients with ST elevation myocardial infarction (STEMI) and those with non-ST elevation acute coronary syndrome (NSTE-ACS). The inclusion criteria for ACS group were age (30-70 years); guideline confirmed acute ≤ 12-hour STEMI and acute ≤ 24-hour NSTE-ACS; and scheduled coronarography with revascularization (urgent for STEMI and early within 24 hours for NSTE-ACS) (13, 14) .
The ACS patients were divided into three subgroups according to coronarography findings: single vessel coronary artery disease (SVCAD) group, double vessel coronary disease (DVCAD) group, and multivessel coronary disease group with three or more coronary arteries involved, including the left coronary artery main trunk (MVCAD).
Control group consisted of 60 age-and sex-matched subjects free from ACS but with at least one of the established risk factors for CAD, including hypertension, DM, obesity, smoking, and hyperlipidemia. Individuals with known recent or previous ACS, or established CVD or chronic disease such as renal or hepatic disease, hyperthyroidism or hyperparathyroidism, sarcoidosis, tuberculosis, autoimmune disease, malabsorption, bone disease, malignancy, pregnancy or lactation, immobility for more than one week, recent vitamin D administration (oral in the last two weeks or injection in the last two months), and receiving drugs affecting vitamin D and calcium metabolism (e.g. corticosteroids or antiepileptic drugs) were excluded. In order to minimize the confounding effect of seasonal fluctuation of 25(OH)D concentration, we tended to involve an equal number of patients each month.
Blood samples were obtained on patient admission. Creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, and total calcium were determined colorimetrically on an AU 680 (Beckman Coulter, Fullerton, USA) auto-analyzer using respective reagents of the same manufacturer. The following demographic and medical data were recorded: age, gender, body mass index (body weight in kilograms divided by the square of height in metres, kg/m (15) .
The study was approved by the Ethics Committee of the Osijek School of Medicine, Josip Juraj Strossmayer University, Osijek. All patients provided their written informed consent.
Prognostic Parameters
Prognosis of ACS patients was assessed according to survival rate for the following MACE: death, reinfarction, target lesion revascularization, cardiac rehospitalization, and stroke during 36-month follow up. Data were collected during medical examination, from medical records and by telephone interview with the patient or patient family member.
Statistics
Categorical variables were presented descriptively and tested by χ 2 -test for between-group differences. Shapiro-Wilk test was employed to test the normality of result distribution of all numerical continuous variables according to the number of patients per group. Of all the variables observed, only vitamin D value showed normal distribution across the sample and within particular groups, whereas all other variables failed to show normal distribution.
Numerical variables with normal distribution were presented with the mean and standard deviation (SD), while between-group differences were analyzed by Student's t-test. Differences in numerical variables with normal distribution among more than two groups were analyzed by ANOVA with post hoc analysis using Tukey HSD post hoc test.
Numerical variables with non-normal distribution were presented with median value and minimal to maximal value range. Between-group differences in numerical variables with nonnormal distribution were analyzed by Mann-Whitney test for two independent samples.
Correlations
The level of statistical significance was set at p < 0.05. Statistical analysis was performed by use of the SPSS for Windows 11.0.3 software (SPSS Inc., Chicago, IL, USA).
RESULTS
The study included 60 ACS patients and 60 patients without ACS as a control group. There were no significant differences in demographic and relevant clinical characteristics between the two groups of patients, except for a statistically significantly higher proportion of smokers in the ACS group as compared with the control group ( Table 1) .
The ACS group included 36 (60%) patients with STEMI and 24 (40%) patients with NSTE-ACS. According to the coronary disease severity assessed by coronarography, patients were divided into subgroups with SVCAD -39 (68%), DVCAD -15 (26%) and MVCAD -3 (6%).
The mean serum concentration of 25(OH)D of 35.19 ± 17.54 nmol/L measured in ACS patients was statistically significantly lower in comparison with control group, where it was 58.08 ± 16.29 nmol/L (Student's t-test, p < 0.001) ( Table 1) .
Use of reference values for vitamin D sufficiency, insufficiency and deficiency yielded a statistically significantly higher rate of vitamin D insufficiency among ACS patients as compared with control group (χ 2 -test, p < 0.001). Vitamin D deficiency was recorded in as many as 20% of ACS patients and none of control subjects (Fig. 1) . There was no statistically significant difference in 25(OH)D serum levels within ACS and control groups according to age and other relevant clinical characteristics, except for DM (Table 1) 
Fig. 1. Significant differences in the proportion of patients with 25(OH)D sufficiency, insufficiency and deficit between ACS and control groups of patients.
of 46.60 ± 19.26 nmol/L in DM patients was also recorded in control group, and this difference was statistically significant (Student's t-test, p < 0.05) (Fig. 2) . In the group of ACS patients, there was no difference in serum 25(OH)D level between STEMI and NSTE-ACS patients. According to CAD severity, the lowest 25(OH)D mean level was measured in patients with MVCAD (31.70 nmol/L). The mean 25(OH)D levels were lower in patients with DVCAD as compared with those with SVCAD (33.65 nmol/L vs. 36.44 nmol/L), however, the difference was not statistically significant (one-way ANOVA, p = 0.818; post hoc Tukey HSD test).
There were no significant correlations of 25(OH)D concentration with BMI, LDL-cholesterol, HDL-cholesterol and triglycerides, but they differed greatly between the ACS group and control group; 25(OH)D correlation with LDL-cholesterol and HDL-cholesterol was positive in ACS patients but negative in control patients. Also, correlation of 25(OH)D and triglycerides was negative in ACS patients but positive in control patients. However, none of these correlations was statistically significant. Positive correlation of 25(OH)D and LDL-cholesterol in ACS patients was close to statistical significance; it was submitted to linear regression analysis, which yielded a weak correlation of these two variables, based on the linear regression curve shape with a great number of outliers, with a low level of correlation (R 2 = 0.059). During 36-month follow up, 40% of study patients suffered MACE. Serum level of 25(OH)D in acute phase was low in ACS patients with MACE, but difference from ACS patients without MACE was not statistically significant (32.64 nmol/L vs. 37.01 nmol/L) (Fig. 3) . The number of ACS patients with MACE recorded during follow up was comparable in all three patient subgroups with normal, insufficient and deficient 25(OH) D serum levels (Fig. 4) .
DISCUSSION
The present study conducted in Croatia compared serum 25(OH)D levels in ACS patients and age-matched non-ACS patients as a control group. Serum 25(OH)D level was statistically significantly lower in the former group of patients. Our results on the high prevalence of vitamin D deficiency or insufficiency in ACS patients (80%) are consistent with literature data associating CVD and numerous CVD risk factors with 25(OH)D deficiency (6, (8) (9) (10) 16) . In addition to the high prevalence of 25(OH)D deficiency in ACS patients, our study confirmed association of demographic characteristics including female gender and DM with vitamin D deficiency (17) .
It should be noted that the study included a homogeneous Caucasian population. Geographically, Croatia lies mostly between latitudes 42° and 46° N, thus preventing vitamin D production in the skin by sun exposure from October to March. Being aware of vitamin D seasonal variation, the study was conducted from March till October (18) .
Study results confirmed significant association between low vitamin D level and higher prevalence of DVCAD and MVCAD (20) . The possible association of vitamin D deficiency and ACS should be additionally elucidated in future studies. The potential mechanisms by which vitamin D insufficiency might lead to an increased cardiovascular risk, directly or indirectly leading to hyperparathyroidism, may include activation of the reninangiotensin system and impaired insulin synthesis, secretion and sensitivity, thus influencing glycemic control and favouring development of DM (21) . Low 25(OH)D levels have also been associated with an increased risk of macrovascular and microvascular complications in DM type 2 (22) .
Other potential sequels of vitamin D deficiency include exacerbation of atherosclerosis, inflammation, and precipitation of arterial calcification. Vitamin D deficiency has been associated with endothelial dysfunction, which in turn is associated with an increased risk of cardiovascular events (23) .
In our study, we demonstrated low serum vitamin D level in the acute phase of ACS; however, we failed to confirm the association of low serum vitamin D level and MACE in ACS patients during 3-year follow up. In recent years, there has been even greater interest in the possible sequels of low vitamin D level in ACS. De Metrio et al. reported the possible correlation between low vitamin D level and increased in-hospital mortality; however, due to the small sample size, they found no difference in mortality between ACS patients with normal and low vitamin D levels (24) . In another study, the authors pointed to the possible independent association of vitamin D deficiency and in-hospital cardiovascular mortality (19) . The largest study assessing vitamin D level and prognosis in ACS patients, conducted by Ng et al., found the lowest vitamin D concentration to be associated with long-term nonfatal MACE in ACS patients (11) .
Our study has some limitations, i.e. only patients hospitalized at a single centre were included. Small study sample reduces the power of event-free survival analysis and the results obtained thus cannot be extrapolated to the overall population of ACS patients. Therefore, these data can only be used to generate some hypotheses, since they offer no evidence supporting the causative relationship; this would require confirmation in an appropriately randomized clinical trial.
In conclusion, vitamin D deficiency is present in the majority of ACS patients, with the lowest vitamin D level measured in diabetic ACS patients. During 3-year follow up, vitamin D failed to prove useful as a prognostic biomarker in ACS patients.
However, the results obtained may prove relevant for public health by pointing to the issue, considering the high prevalence of vitamin D deficiency, aging of the population, polypragmasia contributing to low vitamin D levels, and sedentary lifestyle (25) . Vitamin D deficiency can be treated and vitamin D supplementation is inexpensive; however, we should wait for the results of large randomized interventional studies that will determine whether CVD morbidity and mortality are reduced by vitamin D supplementation.
